CURRICULUM VITAE JOAN GUITART, M.D. Addresses: Home ...

CURRICULUM VITAE
JOAN GUITART, M.D.
Addresses: Home: 1023 Lake Avenue, Wilmette, IL 60091
Work: Northwestern University
The Feinberg Medical School
Department of Dermatology
675 N. Saint Clair Suite 19-150
Chicago, IL 60611
Tel. (312)-695-4174
FAX: (312)-695-0664
e-mail: j-guitart@northwestern.edu
Education: Medical Doctorate (Honors)
Autonomous University of Barcelona, Spain
September 1977 through September 1983
Guitart, 1
Senior Medical Student Exchange in USA 1982-3 (Loyola University-surgery,
University of Illinois-medicine, pathology; Children's Memorial Hospital-pediatrics,
Harvard University-pediatrics and cardiology)
Post-Doctoral
Training: Pathology Residency 1984-88 (Anatomical and Clinical Pathology)
University of Illinois, Chicago IL
Dermatopathology Fellowship 1988-89
Cleveland Clinic Foundation, Cleveland OH
Internship in Internal Medicine 1989-90
Cleveland Clinic Foundation, Cleveland Ohio
Residency in Dermatology 1990-93
University of Illinois, Chicago IL
Past Position: Interim Chairman, Department of Dermatology Northwestern University (2003-04)
Dermatology Residency Program Director NU (2003-04)
Director of Dermatopathology Laboratory, University of Illinois at Chicago (1991-93)
Present Position: Professor of Dermatology and Pathology
Director of Cutaneous lymphoma clinic
Director of Dermatopathology Laboratory
Dermatopathology Fellowship Program Director, NU
Northwestern University Medical School, Chicago, IL
Attending physician, Northwestern Memorial Hospital and Rehabilitation Institute of
Chicago
Committees Member, Medical School Senate 1996-98
Member, Melanoma Committee, National Comprehensive Cancer Network 1998-2004
Member, Executive committee, International Society of Dermatopathology 2000-4
Member, Board of Directors, American Society of Dermatopathology 2003-7

Guitart, 2
Member, Audit Committee, American Society of Dermatopathology 2004
Liaison to the international league of dermatological societies for the American Society
of Dermatopathology, 2003-08
Chair, Pathology committee, International Society of Cutaneous Lymphomas 2003-08
Member, Plans and policies committee Chicago Dermatological Society 2003-
Treasurer, Chicago Dermatological Society 2004-7
Member, American Academy Dermatology World Congress Fund Review Task Force 2005-9
Member, American Board of Pathology, Development and Advisory committee 2006-11
President. Chicago Dermatological Society 2007-08
Member, American Board of Pathology, Dermatopathology task force 2007-2011
Member, Board of Directors, International Society of Cutaneous Lymphomas, 2007-2011
Member, Executive committee, United States Consortium for Cutaneous Lymphomas
Delegate, International League of Dermatological Societies, 2006-
US Exams: Visa Qualifying Examination (Paris, 9/1983)
FLEX (Chicago,12/1984)
ECFMG (Certificate Number 376-116-0)
License: Illinois (036-072199)
DEA # BG3708128
Board Certification: Anatomical and Clinical Pathology, May,1988
Dermatopathology, November,1990
Dermatology, October, 1993 Re-certification 2001
Society
Memberships: Chicago Dermatological Society
Illinois Dermatological Society
American Academy of Dermatology
American Society of Dermatopathology
International Society of Dermatology
International Society of Dermatopathology
Society of Investigative Dermatology
United States Consortium of Cutaneous Lymphomas
North American Melanoma Study Group
International Society of Cutaneous Lymphomas
Awards: First Prize Award on the Thomas Jefferson
Competition on Scientific assays.
The V Inter-Continental Congress of Dermatology
Caracas, Venezuela, February 1993.
International guest Societee Francaise de Dermatologie
International Guest Award at the 1997 annual meeting, Paris, France
Zola Cooper Dermatology Society , San Antonio Texas
2006 Guess Dermatopathologist Award
Ad hook Journal Reviewer
Journal of the American Academy of Dermatology
Lancet
Blood

Archives of Dermatology
British Journal of Dermatology
Journal of the American Medical Association
Journal of Cutaneous Pathology
American Journal of Dermatopathology
Pediatric Dermatology
American Journal of Pathology
Pediatric and Developmental Pathology
Bone Marrow Transplantation
Human Pathology
Journal of Experimental Dermatology
American Journal of Hematology
Clinical and Experimental Dermatology
European Journal of Dermatology
Editorial Board American Journal of Dermatopathology, Dermatology Research & Practice
Publications:
1. Lo JS, Guitart J, Bergfeld WF et.al. Perforating pilomatricoma. Cutis 44;128-9,1989.
Guitart, 3
2. Andreano JM, Camisa C, Guitart J. Clinical features of Urticaria Pigmentosa. Clev Clin J Med 57:259-
65,1990.
3. Helm TN, Guitart J, Bergfeld WF. Occult Syringoma associated with alopecia. Int J Derm 20:9-16,1990.
4. Guitart J, Bergfeld WF, Tuthill RJ et.al. Squamous cell carcinoma of the nailbed: a clinicopathological study
of 12 cases. Br.J Derm 123:215-222,1990.
5. Guitart J, Tubbs R, Bergfeld WF. Granulocytic Sarcoma (letter) Am J Dermpath 1990
6. Helm T, Guitart J,Bergfeld WF. In vivo complement and C3 binding to the intercellular substance and
cytoplasm of epidermal basal cells in a patient with scleroderma and inclusion body myositis. Brief
communication. J Am Acad Derm 23:753-54,1990.
7. Guitart J, Bergfeld WF, Tuthill RJ. Fibrous papule of the nose with granular cells. J Cutan Pathol 18:284-
287,1991.
8. Guitart J, McGillis ST, Bergfeld WF et.al. Muir Torre Syndrome associated with alpha-1- antitrypsin
deficiency and cutaneous vasculitis.Case report. J Am Acad Derm 24:875-7,1991.
9. Lo JS, Guitart J, Bergfeld WF. Granuloma Annulare associated with metastatic adenocarcinoma. Int J Derm
30:9-16,1991.
1. Guitart J, Bergfeld WF, Tuthill RJ. Diffuse Dermal Histiocytosis. Am J Dermpath 13: 174-178,1991.
2. Nederost ST, Bergfeld WF, Valenzuela R, Guitart J, Fleming MG. Cell cycle analysis by flow cytometry of
non-exposed, sun-exposed and tretinoin-treated skin. J Cutan Pathol 19:371-375,1992.
12. Guitart J, McGillis ST, Bailin P, Rodgers R. Verrucous carcinoma of the mouth. Report of an aggressive
tumor. J Derm Sur Onc 19(9):875-877,1993.

Guitart, 4
13. Ronan SG, Uzoaru I, Nadimpalli V, Guitart J. Primary Cutaneous Pheohyphomycosis: Report of seven cases.
J Cutan Pathol 20:3;223-228,1993.
14. Ferrau F, Micali G, Guitart J. Merkel Cell Carcinoma of the scalp: An exceptional presentation with dramatic
resolution after primary chemoyherapy J Am Acad Dermatol 1994;31(2):271-2.
15. Kuzel TM, Guitart J. Current management of Cutaneous T-cell Lymphomas. Contemporary Oncology
4(9):51-60,1994
16. Guitart J, Woodley DT. Intertrigo. A practical approach. Comprehensive Therapy 20(7):402 409,1994.
17. Guitart J, Micali G, Norton SA. Langerhans Cell Histiocytosis presenting as scalp folliculitis. Arch Dermatol
131(6):719-724,1995.
18. Roholt NS, Herrman JJ, Paller AS, Guitart J Cutaneous bronchogenic cyst. Stump the expert. Derm Surg
21(4):284,1995.
19. Roholt N, Eramo L, Guitart J. A gradualy enlarging asymptomatic nasal mass. Cellular neurothekeoma. CPC J
Ped Dermatol 12(2):191-4,1995.
20. Micali G, Guitart J, Nasca MR, Musumeci ML. Bowel bypass syndrome: a case report. Derm Clin 1995:3-
4:197-200
21. Gordon KB, Guitart J, Kuzel T, Eramo L, VonRoenn J. Hand-Food Syndrome Associated with Liposome-
Encapsulated Doxorubicin Therapy. Cancer;75:2169-73, 1995.
22. Gordon KB, Guitart J, Kuzel T, Roenigk H, Rosen S. Pseudo-Mycosis fungoides in a patient taking
clonazepam and fluoxetine. JAAD 1996;34(2)304-6.
23. Guitart J., Ritter JH, Wick MR. Solitary cutaneous myofibromas. Report of six cases and discussion of
differential diagnosis J Cutaneous Pathol 1996:23;437-444
24. Guitart J, Padula M, Caro WA, Roenigk H. Lichenoid changes in mycosis fungoides. J Am Acad Dermatol
1997;36:417-22.
25. Guitart J, Fretzin D. Skin as the primary site of Hodgkin's disease. Does cutaneous Hodgkin's disease exist?
American Journal of Dermatopathology 1998;20(2):218-222.
26. Katz S, Guitart J. Starburst cells are not specific for Lentigo Maligna JAAD 1998;38:283
27. Guitart J, Sichi R, Gordon K. Evolution of cutaneous lesions is not a reliable measurement of disease activity
in histiocytic cytophagic panniculitis. JEADV1998;10:267-268
28. Lapiere JC, Guitart J, Ettlin DA et al. Preferential activation of the complement system in the lower epidermis
of pemphigus vulgaris patients. Br J Dermatol 1998;139:851-54
29. Guitart J, Kaul K. new polymerase chain reaction-based method for the detection of T-cell clonality in patients
with possible cutaneous T-cell lymphoma. Archives of Dermatology 1999;135:158-162
30. Guitart J, Variakojis D, Kuzel T, Rosen S. CD8+ cutaneous lymphoid infiltrates in advanced HIV infection
(JAAD 1999;41:722-7)

31. Guitart J, Gordon K. Keratoacanthomas and lymphomatoid papulosis. American Journal of
Dermatopathology 1998;20(4):431-32.
Guitart, 5
32. Rosen ST, Guitart J, Kuzel TM. Early detection of cutaneous lymphoma. Article review. Oncology
1998;12(10):1532-24
33. Houghton A, Coit D, Bloomer W, Buzaid A, Chu D, Eisenburgh B, Guitart J, Johnson T, Miller S, Sener S,
Tanabe K, Thompson J, Urist M, Walker M. Melanoma practice guidelines. National Comprehensive Cancer
Network. Oncology 1998;12:153-77
34. Burt RK, Guitart J, Traynor A, Lin K, Rosen S, Kuzel TM. Allogeneic hematopoietic stem cell
transplantation for advanced mycosis fungoides: Evidence of graft-versus-tumor effect. Bone marrow
transplantation 2000;25:111-3
35. Guitart J, Hurt MA. Pleomorphic T-cell infiltrate associated with molluscum contagiosum. American Journal
of Dermatopathology 1999;21(2):178-180
36. Dolan ME, McRae, BL, Ferries-Rowe E, Belanich M, van Seventer GA, Guitart J, Pezen D, Kuzel TM,
Yarosh DB. 06-Methylguanine DNA methyltransferase in cutaneous T-cell lymphomas: Implications for
treatment with alkylating agents. Clinical Cancer Research 1999;5:2059-64
37. O’Toole EA, Mak LL, Guitart J, Woodley DT, Amagai M, Chan LS. Induction of keratinocyte interleukin-8
expression and secretion by IgG autoantibodies as a novel mechanism of epidermal neutrophil recruitment in a
pemphigus variant. Clinical and Experimental Immunology 2000;119:217-24
38. Li-Cheng Wu M, Guitart J. Low specificity of CD20 in the diagnosis of extramammary Paget’s disease
(letter). Br J Dermatol. 2000 Mar;142(3):569.
39. Guitart J Hypereosinophilic syndrome (letter). N Engl J Med. 2000 Mar 2;342(9):659-60
40. Pandolfino TL, Siegel RS, Guitart J, Kuzel TM, Rosen ST. Primary cutaneous B cell lymphomas: Review
and current concepts J Clin Oncol 18:2152-68, 2000
41. Wu ML, Richards KA, Caro WA, Guitart J. Atypical reexcision perineural invasion. Am J Surg Path
2000;24:895-6
42. Guitart J HIV-1 and an HTLV-II-associated cutaneous T-cell lymphoma.
N Engl J Med. 2000 Jul 27;343(4):303-4.
43. Siegel RS, Pandolfino T, Guitart J, Rosen S, Kuzel TM Primary Cutaneous T-Cell Lymphoma: Review and
Current Concepts.
J Clin Oncol. 2000 Aug 15;18(15):2908-2925
44. Wu ML, Guitart J Low specificity of cytokeratin 20 in the diagnosis of extramammary Paget's disease. Br J
Dermatol 2000 Mar;142(3):569
45. Wu ML, Guitart J Unusual neurotropism. Am J Dermatopathol. 2000 Oct;22(5):468-9.
46. Guitart J, Kennedy J, Ronan, S, Chmiel JS, Hsiegh YC, Variakojis D. Histologic criteria for the diagnosis of
mycosis fungoides: proposal for a grading system to standardize pathology reporting. J Cut Pathol 2001:
28(4):174-83

Guitart, 6
47. Wood GS, Kamath NV, Guitart J, Heald P, Kohler S, Smoller BR, Cerroni L. Absence of Borrelia burgdorferi
DNA in cutanoeus B-cell lymphomas from the United States. J Cutan Pathol 2001;28:502-507
48. Jean-Baptiste S, O'Toole EA, Chen M, Guitart J, Paller A, Chan LS. Expression of eotaxin, an eosinophilselective
chemokine, parallels eosinophil accumulation in the vesiculobullous stage of incontinentia pigmenti.
Clin Exp Immunol 2002 Mar;127(3):470-8
49. Guitart J, Lowe L, Piepkorn M et al. Histological characteristics of thin metastasizing melanomas: a casecontrol
study of 43 cases. Arch Dermatol 2002;May;138(5):603-8
50. Tucker RL, Guitart J, Goolsby C, Variakojis D. Flowcytometric, immunophenotyping in cutaneous
lymphomas. Cytometry 2002
51. Tucker RL, Guitart J. Adamantinoid basal cell carcinoma. Immunohistochemical analysis and review of the
literature. (Submitted Am J Dermatopathol)
52. Guitart J, Wickless SC, Oyama Y, Kuzel TM, Rosen ST, Traynor A, Burt R. Long-term remission after
allogeneic hematopoietic stem cell transplantation for refractory cutaneous T cell lymphoma. Arch Dermatol
2002;138:1359-1365
53. Wu JJ, Sanchez-Palacios C, Brieva J, Guitart J. A case of air bag dermatitis. Arch Dermatol. 2002
Oct;138(10):1383-4.
54. Pichardo RO, Lu D, Sangueza OP, Guitart J. What is your diagnosis? Diffuse dermal angiomatosis secondary
to anitcardiolipin antibodies. Am J Dermatopathol 2002 Dec;24(6):502-3
55. Guitart J, Lowe L, Piepkorn M, Prieto VG, Rabkin MS, Shea CR, White W, Barnhill RL. Metastasizing thin
melanoma or multiple primary melanomas? Arch Dermatol 2003 Mar;139(3):388-9
56. Guitart J ,Rosenbaum MM, Requena L. “Eruptive syringoma”: a misnomer for a reactive eccrine glandular
ductal proliferation. J Cut Pathol 2003;Mar 30:202-205
57. Guitart J, Camisa C, Ehrlich M, Bergfeld W. Long term implications of T Cell Receptor Gene Rearrangement
Analysis by Southern blot in patients with Cutaneous T cell Lymphoma J Am Acad Dermatol 2003
May;48(5):775-9
58. Robinson N, Guitart J. Etenercept for the treatment of recalcitrant apthous stomatitis. Arch Dermatol Oct
2003;139:125912-62
59. Wu J, Guitart J, Tucker R, Kuzel TM, Rosen ST. Secondary cutaneous anaplastic large cell lymphoma treated
with liposomal doxorubicin leading to complete. Int JDermatol 2003 Jun;42(6):464-5
60. Prieto VG, Argenyi ZB, Barnhill RL, Duray PH, Elenitsas R, From L, Guitart J et al. Are en face frozen
sections accurate for diagnosing margin status in melanocytic lesions? Am J Clin Pathol. 2003;120(2):203-8
61. Querfeld C, Guitart J, Kuzel TM, Rosen ST.Primary cutaneous lymphomas: a review with current treatment
options Blood Rev. 2003 Sep;17(3):131-42
62. Querfeld C, Rosen ST, Kuzel TM, Guitart J Cutaneous T-cell lymphomas: A review with emphasis on new
treatment approaches Semin Cutan Med Surg 22 (3): 150-161, 2003
63. Oyama Y, Guitart J, Kuzel TM, Burt RK, Rosen ST. High-dose therapy and bone marrow transplantation in
cutaneous T-cell lymphoma. Hematol Oncol Clin North Am. 2003 Dec;17(6):1475-83

Guitart, 7
64. Pichardo D, Querfeld C, Guitart J, Kuzel T, Rosen S. Cutaneous T-Cell Lymphoma: A Paradigm for
Biological Therapies. Leuk Lymphoma. 2004;45(9):1755-1765
65. Querfeld C, Rosen ST, Guitart J et al. Comparison of selective retinoic acid receptor- and retinoic X receptormediated
efficacy, tolerance, and survival in cutaneous t-cell lymphoma. J Am Acad Dermatol. 2004 Jul;51(1
Pt 1):25-32.
66. Sanchez-Palacios C, Guitart J. Hydroxyurea-associated squamous dysplasia. J Am Acad Dermatol. 2004
Aug;51(2):293-300.
67. Horn KB, Horn MA, Swan J, Singhal S, Guitart J. A complete and durable clinical response to high-dose
dexamethasone in a patient with scleromyxedema. J Am Acad Dermatol. 2004 Aug;51(2 Suppl):S120-3.
68. Querfeld C, Guitart J, Kuzel TM, Rosen S. Successful treatment of recalcitrant, erythroderma-associated
pruritus with etanercept. Arch Dermatol. 2004 Dec;140(12):1539-40.
69. Oyama Y, Parker ER, Brieva J, Guitart J, Statkute L, Verda L, Burt RK. High-dose immune suppression and
autologous hematopoietic stem cell transplantation in refractory pemphigus foliaceus. Bone Marrow
Transplant. 2004 Dec;34(12):1097-8.
70. Ramirez JA, Laskin WB, Guitart J. Lymphangioma-like Kaposi sarcoma. J Cutan Pathol. 2005
Apr;32(4):286-92.
71. Querfeld C, Rosen ST, Kuzel TM, Kirby KA, Roenigk HH Jr, Prinz BM, Guitart J Long-term follow-up of
patients with early-stage cutaneous T-cell lymphoma who achieved complete remission with psoralen plus UV-
A monotherapy. Arch Dermatol. 2005 Mar;141(3):305-11.
72. Querfeld C, Rosen ST, Guitart J, Kuzel TM The spectrum of cutaneous T-cell lymphomas: new insights into
biology and therapy. Curr Opin Hematol. 2005 Jul;12(4):273-8.
73. Ramirez JA, Guitart J, Rao MS, Diaz LK. Cyclin D1 expression in melanocytic lesions of the skin.
Ann Diagn Pathol. 2005 Aug;9(4):185-8.
74. Pimpinelli N, Olsen EA, Santucci M, Vonderheid E, Haeffner AC, Stevens S, Burg G, Cerroni L, Dreno B,
Glusac E, Guitart J, Heald PW, Kempf W, Knobler R, Lessin S, Sander C, Smoller BS, Telang G, Whittaker
S, Iwatsuki K, Obitz E, Takigawa M, Turner ML, Wood GS; International Society for Cutaneous Lymphoma.
Defining early mycosis fungoides. J Am Acad Dermatol. 2005 Dec;53(6):1053-63.
75. Guitart J. Beyond clonal detection: defining the T-cell clone. Arch Dermatol. 2005 Sep;141(9):1159-60.
76. Alam M, Levy R, Pavjani U, Ramierez JA, Guitart J, Veen H, Gladstone HB. Safety of radiofrequency
treatment over human skin previously injected with medium-term injectable soft-tissue augmentation materials:
A controlled pilot trial. Lasers Surg Med. 2006 Mar;38(3):205-10.
77. Guitart J. Combination Treatment Modalities in Cutaneous T-Cell Lymphoma (CTCL). Semin Oncol. 2006
Feb;33(1 Suppl 3):17-20.
78. Querfeld C, Naguelli LV, Kuzel T, Rosen ST, Guitart J Bexarotene in the treatment of cutaneous T-cell
lymphoma. Expert Opin Pharmacother. 2006 May;7(7):907-15

Guitart, 8
79. Querfeld C, Rizvi MA, Kuzel TM, Guitart J, Rademaker A, Sabharwal SS, Krett NL, Rosen ST. The Selective
Protein Kinase C beta Inhibitor Enzastaurin Induces Apoptosis in Cutaneous T-Cell Lymphoma Cell Lines
through the AKT Pathway. J Invest Dermatol. 2006;126(7):1641-7.
80. Guitart J What's New in Cutaneous T-Cell Lymphomas: 2006. Semin Cutan Med Surg. 2006 Jun;25(2):87-90.
81. Gerami P, Guitart J. Folliculotropic Sezary syndrome: a new variant of cutaneous T-cell lymphoma. Br J
Dermatol. 2007 Apr;156(4):781-3
82. Luu M, Lai SE, Patel J, Guitart J, Lacouture ME. Photosensitive rash due to the epidermal growth factor
receptor inhibitor erlotinib. Photodermatol Photoimmunol Photomed. 2007 Feb;23(1):42-5.
83. Guitart J, Ramirez J, Laskin WB. Cellular digital fibromas: what about superficial acral fibromyxoma? J
Cutan Pathol. 2006 Nov;33(11):762-3
84. Shors AR, Kim S, White E, Argenyi Z, Barnhill RL, Duray P, Erickson L, Guitart J, Horenstein MG, Lowe L,
Messina J, Rabkin MS, Schmidt B, Shea CR, Trotter MJ, Piepkorn MW. Dysplastic naevi with moderate to
severe histological dysplasia: a risk factor for melanoma. Br J Dermatol. 2006 Nov;155(5):988-93.
85. Ersoy-Evans S, Sahin S, Mancini AJ, Paller AS, Guitart J. The acanthosis nigricans form of epidermal nevus.
J Am Acad Dermatol. 2006 Oct;55(4):696-8.
86. Querfeld C, Rosen ST, Guitart J, Rademaker A, Foss F, Gupta R, Kuzel TM. Phase II trial of subcutaneous
injections of human recombinant interleukin-2 for the treatment of mycosis fungoides and Sezary syndrome. J
Am Acad Dermatol. 2007 Apr;56(4):580-3.
87. Querfeld C, Kuzel T, Rosen S, Guitart J. Primary cutaneous CD30+ lymphoproliferative disorders: new
insights into biology and therapy. Oncology (Williston Park). 2007 May;21(6):689-96;
88. Guitart J, Magro C “Cutaneous T cell lymphoid dyscrasia: A unifying term for idiopathic chronic dermatosis
with persistent T cell clones” Arch Dermatol. 2007 Jul;143(7):921-32.
89. Dyer JA, Guitart J, Klein-Gitelman M, Mancini AJ. Neutrophilic panniculitis in infancy: a cutaneous
manifestation of juvenile rheumatoid arthritis. J Am Acad Dermatol. 2007 Nov;57(5 Suppl):S65-8.
90. Gerami P, Guitart J. Panniculitis with histiocytoid/immature neutrophils is not limited to histiocytoid
panniculitic Sweet syndrome. Am J Dermatopathol. 2007 Dec;29(6):596. No abstract available. PMID:
18032966
91. Gerami P, Guitart J. Basaloid folliculolymphoid hyperplasia: a distinctive finding in follicular mycosis
fungoides.J Cutan Pathol. 2007 Dec;34 Suppl 1:29-32
92. Kelemen K, Guitart J, Kuzel TM, Goolsby CL, Peterson LC. The usefulness of CD26 in flow cytometric
analysis of peripheral blood in Sézary syndrome. Am J Clin Pathol. 2008 Jan;129(1):146-56. PMID: 18089499
93. Barnhill RL, Argenyi Z, Berwick M, Duray PH, Erickson L, Guitart J, Horenstein MG, Lowe L, Messina J,
Paine S, Piepkorn MW, Prieto V, Rabkin MS, Schmidt B, Selim A, Shea CR, Trotter MJ. Atypical cellular blue
nevi (cellular blue nevi with atypical features): lack of consensus for diagnosis and distinction from cellular
blue nevi and malignant melanoma ("malignant blue nevus"). Am J Surg Pathol. 2008 Jan;32(1):36-44.PMID:
18162768

Guitart, 9
94. Xie X, Sundram U, Natkunam Y, Kohler S, Hoppe RT, Kim YH, Cook JR, Hammel J,Swerdlow SH, Guitart
J, Smith MD, Bosler D, Listinsky C, Lossos IS, Hsi ED. Expression of HGAL in primary cutaneous large Bcell
lymphomas: evidence for germinal center derivation of primary cutaneous follicular lymphoma. Mod
Pathol. 2008 21 (issue 6): 653-659
95. Guitart J, Gerami P.Touton-like giant cells in a Spitz's nevus. J Cutan Pathol. 2008 Feb 28
96. Gerami P, Guitart J. The spectrum of histopathologic and immunohistochemical findings in folliculotropic
mycosis fungoides. Am J Surg Pathol. 2007 Sep;31(9):1430-8
97. Guitart J "Lymphocytic vasculitis" is not urticarial vasculitis. J Am Acad Dermatol. 2008 Aug;59(2):353.
98. Gerami P, Rosen S, Kuzel T, Boone SL, Guitart J. Folliculotropic mycosis fungoides: an aggressive variant of
cutaneous T-cell lymphoma. Arch Dermatol. 2008 Jun;144(6):738-46.
99. Lacouture ME, Reilly LM, Gerami P, Guitart J. Hand foot skin reaction in cancer patients treated with the
multikinase inhibitors sorafenib and sunitinib. Ann Oncol. 2008 Jun 10.
100. Lee C, Ramirez JA, Guitart J, Diaz LK. Expression of cyclooxygenase-2 and peroxisome proliferatoractivated
receptor gamma during malignant melanoma progression. J Cutan Pathol. 2008 Jun 4.
101. Gerami P, Wickless SC, Rosen S, Kuzel TM, Ciurea A, Havey J, Guitart J. Applying the new TNM
classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome in
primary cutaneous marginal zone lymphoma. J Am Acad Dermatol. 2008 Aug;59(2):245-54.
102. Gerami P, Guitart J, Rosen S, Kuzel TM. Interleukins in the treatment of mycosis fungoides. G Ital Dermatol
Venereol. 2008 Feb;143(1):55-8
103. Nguyen V, Huggins RH, Lertsburapa T, Bauer K, Rademaker A, Gerami P, Guitart J. Cutaneous T-cell
lymphoma and Staphylococcus aureus colonization. J Am Acad Dermatol. 2008 Dec;59(6):949-52.
104. Guitart J, Gerami P. Is there a cutaneous variant of marginal zone hyperplasia? Am J Dermatopathol. 2008
Oct;30(5):494-6.
105. Gerami P, Guitart J, Martini M, Wayne JD, Kuzel T. Cyclin D1 homogeneous staining regions by fluorescent
in situ hybridization: a possible indicator of aggressive behavior in melanomas. Arch Dermatol. 2008
Sep;144(9):1235-6.
106. Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I,
Alexandrescu DT, Anderson RT, Wood L, Dutcher JP. Evolving strategies for the management of hand-foot
skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist. 2008
Sep;13(9):1001-11.
107. Boone SL, Guitart J, Gerami P. Follicular mycosis fungoides: a histopathologic, immunohistochemical, and
genotypic review G Ital Dermatol Venereol. 2008 Dec;143(6):409-14
108. Leu S, Gerami P, Guitart J, Brieva J. Acral atrophic papules, petechia, and patches of alopecia. Syringotropic
mycosis fungoides Arch Dermatol. 2009 Jan;145(1):77-82.
109. Gerami P, Jewell SS, Morrison LE, Blondin B, Schulz J, Ruffalo T, Matushek P, Legator M, Jacobson K,
Dalton SR, Charzan S, Kolaitis NA, Guitart J, Lertsbarapa T, Boone S, Leboit PE, Bastian BC. Fluorescence
In Situ Hybridization(FISH) as an Ancillary Diagnostic Tool in the Diagnosis of Melanoma. Am J Surg Pathol.
2009 Jun 24

Guitart, 10
110. Mirzabeigi M, Guitart J, Gerami P. Primary cutaneous malignant melanoma with pseudorosettes features. An
unusual morphological manifestation. Am J Dermatopathol. 2009 Jun;31(4):403-5.
111. Pouryazdanparast P, Newman M, Mafee M, Guitart J, Gerami P. Malignant melanomawith monster cells
showing massive cyclin D1 amplification. Am J Dermatopathol. 2009 Jun;31(4):402-3. PubMed PMID:
19461251.
112. Newman MD, Lertsburapa T, Mirzabeigi M, Mafee M, Guitart J, Gerami P. Fluorescence in situ hybridization
as a tool for microstaging in malignant melanoma. Mod Pathol. 2009 May 15. [Epub ahead of print]
Chapters:
1. Knox J, Solomon LM, Guitart J. Neurological complications of dermatologic disease and their treatment.
(Volume I) Elsevier Science Publications, Amsterdam,The Netherlands 1993.
2. Guitart J, Micali G, Solomon LM. Localized Scleroderma. In: Scleroderma, Furst and Clements (Editors)
Williams & Wilkins, Maryland, 1995.
3. Micali G, Guitart J, Solomon LM. Genodermatosis. In: Pediatric Dermatology. Schachner LA, Hansen RC
(Editors). Churchill-Livingstone, New York 1995.
4. Kuzel TM, Guitart J. Evaluation and treatment of mycosis fungoides and the Sezary syndrome. In:
Immunomodulatory and cytotoxic agents in Dermatology. McDonald CJ (Editor).Marcel Dekker New York
1997.
5. Guitart, J. Spongiotic Dermatitis. In: Pathology of the Skin. Farmer E, Hood AH (Editors) Appleton & Lange
Norwalk CN 1999
6. Kuzel TM, Guitart J, Rosen S. Cutaneous T-cell lymphomas. In: Hematology: Basic principles and practice.
Hoffman R (Editor) Churchill-Livingston, New York 1998
7. Guitart J, Burt R. Hematopoietic Stem Cell Transplantation in Patients with Autoimmune Bullous Skin
Disorders. In: Stem Cell Therapy of Autoimmune Bullous Diseases. Burt and Marmont (Editors) Landes
Bioscience 2004
8. Prinz M, Guitart J Diagnostic Evaluation. In: Psoriasis and Psoriatic Arthritis: An Integrated Approach. K
Gordon E Ruderman (Editors) Springler 2005
9. Wickless S, Guitart J Melanocytic Nevi. In: Conn’s Current Therapy. Editor R Rakel. Elsevier. Oxford UK
2005
10. Parker E, Guitart J. Candidal Intertrigo Up to Date 2006 (online evidence-based clinical information)
11. Querfeld C, Kuzel T, Guitart J, Rosen S. Treatment approach to cutaneous lymphomas. In: Clinical
Malignant Hematology. Sekeres, Kalaycio, Bolwell (Editors) McGraw Hill 2007

Guitart, 11
12. Magro C, Guitart J, Crowson N. Precursor lesions of CTC. In: The cutaneous lymphoid proliferations.
Magro, Crowson, Mihm (Editors) Wiley VCH. Berlin, Germany 2008
13. Querfeld C, Rosen S, Guitart J. Chapter 24: Primary Cutaneous T cell lymphomas. Editor: J Armitage, N
Harris (In press)
14. Querfeld C, Rosen S, Guitart J. Chapter 30: Primary Cutaneous CD30 lymphoproliferative disorders. Editor: J
Armitage, N Harris (In press)
Editorials:
Guitart J. “Pathogenesis of Stevens-Johnson’s Syndrome” Allergy Proceedings, 1995 16(4):163-4.
Guitart J. “Beyond clonal detection: defining the T cell clone” Arch Dermatol Sep 2005
Posters and
Presentations:
1. Generalized Woringer-kolopp or Epidermotropic CTCL. Presentation at the Chicago Registry of Pathology,
1987.
2. Hurthle cell neoplasia of the thyroid gland. Presentation at the 21st Annual Meeting of the Illinois Society of
Cytopathology. Chicago1987.
3. DNA flow cytometry and cell analysis system (CAS) morphometry of basal cell carcinoma Annual Meeting of
ASDSO, Chicago, 1990.
4. Histopathology of Subacute Cutaneous Lupus Erythematosus. Poster at the 27th Annual Meeting of the ASDP,
San Francisco, 1989.
5. Alopecia Associated with Eccrine Ductal Proliferation. (Poster and presentation) Annual meeting of ASDP and
AAD, San Francisco,1989.
6. Tissue evaluation of lesions suspicious of CTCL. Poster at the 27th Annual Meeting of ASDP San
Francisco,1989.
7. Squamous Cell Carcinoma of the nailbed: Study of 12 cases. Poster at the 1989 Meeting of the International
Soc of Dermpath, Charleston, SC 1989.
8. Merkel Cell Tumor. Report of an Unusual presentation. Italian Society of Dermatology Rome 1993.
9. Primary cutaneous Hodgkin’s disease. Poster. ASDP Annual Meeting.Washington February 1996.
10. Lichenoid Mycosis Fungoides. Poster. ASDP Annual Meeting. Washington, February 1996.
11. Cutaneous T-cell lymphoma in HIV population. Oral presentation ASDP Annual Meeting, Washington
February, 1996.
12. Solitary cutaneous myofibromas. Oral presentation. ASDP Annual Meeting, Washington February, 1996.
13. Development of an animal model for cutaneous T-cell lymphoma. Soc Invest Dermatol. Washington May1996.
14. Rapid Assay for the detection of clonal cutaneous T-cell populations by single stranded conformation
polymorphism analysis combined with polymerase chain reaction. Soc Invest Dermatol. Washington May
1996.
15. Immunophenotypic comparison of reactive dermatosis, atypical lymphoid infiltrates and mycosis fungoides.
Lab Invest 1997; 76:1128A US & Canadian Acad Pathology Orlando FL November 1996.
16. Eotaxin, an eosinophil-specific chemoattractant, is upregulated in bullous pemphigoid lesional epidermis and in
normal human keratinocytes stimulated by a pro-inflammatory cytokine IL-1a. Society Investigative
Dermatology May 1997.
17. Activation of IL8 secretion in pemphigus herpetiformis by antidesmoglein 1 IgG antibodies. (abstract) JID
1998;110:509
18. The role of eotaxin an eosinophilic-specific chemokine in the blistering process of incontinentia pigmenti.
Society of Investigative Dermatology, May 1999
19. Topical triamcinolone and tacrolimus differ in their in vitro effects on Langerhans cells during treatment of
atopic dermatitis. Society of Investigative Dermatology Chicago, May 1999

Guitart, 12
20. Phase II trial of all-trans retinoic acid (ATRA) in the treatment of relapsed/refractory mycosis fungoides Sezary
syndrome. American Society of Hematology 1999
21. Cycloxigenase-2 is not expressed in the hyperproliferative epidermis of psoriasis but is expressed in lichen
planus and actinic keratosis. International Symposium on Psoriasis. London November 1999
22. Utility of flow cytometry in immunophenotyping in cutaneous lymphoma. American & Canadian Academy of
Pathology Meeting New Orleans, March 1999
23. Perineural invasion in reexcision specimens International Soc Dermatopathology meeting San Francisco March
2000
24. T cell receptor gene rearrangement study in mycosis fungoides; Long term follow- up. SID annual meeting
Chicago May 2000 (JID 2000;114:806)
25. Adamantinoid basal cell carcinoma. Joint meeting of the ISD. Washington March 2001(AJDP 2001;23:358)
26. Borrelia burgdorferi is absent in cutanoeus B cell lymphomas within the united states. Kamath NV, Wood GS,
Guitart J et al. SID annual meeting Washington DC May 2001 (JID 2001)
27. Phase II Trial of Temozolomide (TMZ) for Treatment of Mycosis Fungoides/Sezary Syndrome
(MF/SS)American Society of Oncology 2001
28. Ganglioside gene modulation leads to increased tumorigenicity in a mouse squamous cell carcinoma model.
SID annual meeting Los Angeles May 2002 (JID2002)
29. Low dose bexarotene capsules and phototherapy for early stage cutaneous T cell lymphoma. . SID annual
meeting Los Angeles May 2002 (JID2002)
30. Immunophenotyping of B cell lymphomas by flow cytometry. World Congress of Dermatology . Paris July
2002
31. Phase II trial of temozolomide (TMZ) for treatment of mycosis fungoides/sezary syndrome (MF/SS). ASCO
2002
32. Immunophenotyping of cutaneous B cell lymphomas by flow Cytometry analysis. Platform presentation.
Annual meeting of the International Society of Dermatopathology. Berlin, Germany September 2002
33. Immunophenotyping of cutaneous B cell lymphomas with flow cytometry. International Investigative
Dermatology Meeting Miami, FL May 2003
34. Efficacy, survival and toxicity of retinoids in the management of CTCL Querfelt Ch, Guitart J, Rademaker A,
Rosen ST, Kuzel TM. European Acad Dermatology & venereology Barcelona 2003
35. Laminin 5 expression in melanocytic lesions. Ramirez J, Diaz L, Guitart J. ASDP Boston Oct 2004
Invited Faculty/Lectures
1. Lecturer, Medical College of Wisconsin. Dermatology grand rounds. “Cutaneous B-cell lymphomas”
Milwaukee June 1993.
2. Course Faculty, “CTCL: new therapeutical tools” American Academy of Dermatology Meeting, New Orleans
February 1995.
3. Course Faculty, “Mycosis Fungoides and related conditions” Hawaii Dermatology Symposium, Maui March
1995.
4. Director and course faculty, “Cutaneous lymphomas, leukemias and histiocytosis” Northwestern
Dermatopathology Workshop, Chicago April 1995.
5. Course Faculty, “Self-Assessment Dermatopathology Course” American Academy of Dermatology Summer
Meeting, Chicago July 1995.
6. Co-Director “Chicago best cases” American Academy of Dermatology Summer Meeting, Chicago July 1995.
7. Course Faculty, Second Annual Midwest Dermatopathology Symposium, Indiana University Medical Center,
Indianapolis April 1996.
8. Course Faculty, Dermatopathology Self-assessment Workshop, Cleveland Clinic Foundation, October 1996.
9. Lecturer, “XXI Congreso Nacional de Dermatologia”, Colombian Society of Dermatology, Medillin November
1996.
10. Director, Session on Lymphoproliferative diseases, American Society of Dermatopathology Annual Meeting,
San Francisco, March 1997
11. Lecturer, “ Cutaneous B-cell lymphomas and pseudolymphomas”, American Academy of Dermatology Annual
Meeting, San Francisco, March 1997.

Guitart, 13
12. Director and course faculty, Third Midwest Dermatopathology Workshop, Chicago, April 1997
13. Lecturer, “Mesenchymal tumors” Fourth Midwest Dermatopathology Workshop, Saint Louis MO April 1998
14. Lecturer, “ HIV-related lymphomas” International Society of Dermatopathology Annual Meeting, Madrid,
November 1998
15. Panelist, self -assessment session, International Society of Dermatopathology, New Orleans, March 1999
16. Speaker, Hawaii Dermatology seminar, Maui February 1999
17. Director and course faculty, “Bullous diseases of the skin” Northwestern Dermatopathology Workshop,
Chicago April 1999
18. Committee member international society of cutaneous lymphomas. Consensus conference on diagnosis of
mycosis fungoides . Zurich, Switzerland May 1999
19. Panelist, Clinical pathological conference, American Academy of Dermatology July 1999
20. Panelist, self -assessment session, International Society of Dermatopathology, San Francisco February 2000
21. Lecturer, grand rounds University of Pittsburgh October 2000
22. Lecturer, grand rounds Springfield (SIU) October 2000
23. Panelist “Truly new concepts in dermatopathology” International Society of Dermatopathology, Washington
DC February 2001
24. Focus session: “What’s new in cutaneous lymphomas” American Academy of Dermatology Annual Meeting,
Washington DC, March 2001.
25. “Biological therapy in CTCL” Workshop Academy 2001, Anaheim, California July 2001
26. Panelist “cutaneous pseudolymphomas session” International Society of Dermatopathology Stresa, Italy Oct
2001
27. Lecturer for Ph.D., clinical pharmacology program, University of Catania, Italy Oct 2001
28. Director and course faculty, “Pathology of cutaneous lymphomas” Seventh Midwest Dermatopathology
Workshop, Chicago April 2002
29. Panelist. Prognostic indicators in cutaneous Tcell lymphoma . Meeting of the International Society of
Cutaneous Lymphomas. Paris. June 2002
30. Panelist. Evening case discussion session for the Annual Meeting of the American Society of
Dermatopathology. Phoenix AZ October 2002
31. Lecturer. Implications of pathology in the staging of in cutaneous Tcell lymphoma . Meeting of the
International Society of Cutaneous Lymphomas. San Francisco March 2003
32. Organizing committee and moderator of “Dermatopathology reporting session” of the 6 th Joint Meeting of the
International Society of Dermatopathology. San Francisco March 2003
33. Focus session: “What’s new in cutaneous lymphomas” American Academy of Dermatology Annual Meeting,
San Francisco, March 2003
34. Grand Rounds speaker, University of Wisconsin Dept of Dermatology, June 2003
35. Grand Rounds speaker, University of California San Francisco, September 2003
36. Grand Rounds speaker, Wayne State University Dept of Dermatology, October 2003
37. Lecturer, Am Society of Dematopathology 40 th Annual Meeting “ Critical decisions in dermatology and their
diagnostic implications.” Chicago October 2003
38. Panelist “self-assessment” International Society of Dermatopathology Washington DC Feb 2004
39. Faculty Symposium “ Advances in Medical Dermatology” American Academy of Dermatology Annual
Meeting Washington DC Feb 2004
40. Faculty Symposium “ Diagnostic Update” American Academy of Dermatology Annual Meeting Washington
DC Feb 2004
41. Director Discussion Group Session: “Cutaneous T cell lymphomas” American Academy of Dermatology
Annual Meeting Washington DC Feb 2004
42. Speaker, Chicago Dermatological Society, Sillas Walk day of learning, April 2004
43. Lecturer and moderator of self-assessment course. Latin-American Society of Dermatopathology, Lima, Peru
May 2004
44. Speaker, “Cutaneous lymphoid dyscrasias” Int Society of Dermatopathology , Lisbon Portugal September 2004
45. Lecturer “18 th Clinical Seminar in Dermatology” Cleveland, OH Oct 2004
46. Speaker “ Hot topics in dermatopathlogy” ASDP Annual Meeting Boston Oct 2004
47. Speaker “Past, present and future developments in CTCL symposium” Nov 2004 Milan, Italy

Guitart, 14
48. Grand Rounds speaker, University of Chicago, November 2004
49. Grand Rounds speaker, University of Minnesota, January 2005
50. Chairman, Current Issues in Cutaneous Lymphoma Session. ISDP/ISCL joint meeting New Orleans, February
2005
51. Director Discussion Group Session: “Cutaneous T cell lymphomas” American Academy of Dermatology
Annual Meeting New Orleans Feb 2005
52. Faculty Symposium “ Advances in Medical Dermatology” American Academy of Dermatology Annual
Meeting New Orleans Feb 2005
53. Lecturer “An algorithmic approach to cutaneous lymphomas” US and Canada Academy of Pathology Annual
Meeting , San Antonio, February 2005
54. Speaker “Phototherapy and combination therapy in CTCL” Cutaneous Lymphomas Masters Symposium
Dallas April 2005
55. Speaker, Hawaii Dermatology seminar, Maui February 2005
56. Speaker, Pittsburgh Academy of Dermatology, May 2005
57. Speaker for the Elliott Wallach Lectureship at Washington University, June 2005
58. Grand Rounds Speaker, University of Illinois, June 2005
59. Grand Rounds speaker, Dept Dermatology Ohio State University Oct 2005
60. ASDP Annual Meeting Seattle Oct 2005 “Consultations in dermatopathology”
61. Zola Cooper Dermatopathology Seminar. Guest Dermatopathologist San Antonio TX Nov 2005
62. Director “ Impact of clinical information in dermatopathology” session ISDP San Francisco March 2006
63. Moderator of scientific abstract session Annual ISDP meeting in San Francisco 2006
64. Director Discussion Group Session: “Cutaneous T cell lymphomas” American Academy of Dermatology
Annual Meeting San Francisco March 2006
65. Faculty Symposium “ CTCL: skin-directed therapeutic strategies” American Academy of Dermatology Annual
Meeting New Orleans Feb 2005
66. Speaker Italian Therapeutics Symposium. “Update on CTCL” Catania Sicily Feb 2006
67. Speaker IBD Snowbird Symposium on “Dermatosis associated with IBD” Snowbird, UT March 2006
68. Pathology grand Rounds Speaker MD Anderson Cancer Center Houston TX April 2006
69. Grand Rounds Speaker, Case Western Reserve University March 2006
70. Grand Rounds Speaker Ohio State University, Columbus April 2006
71. Guest Speaker. Utah Dermatological Society. Moab UT May 2006
72. Hilton Head Dermatopatohlogy Scientific symposium. Speaker June 2006
73. Guest lecturer, International Academy of Pathology Annual Meeting, Montreal , “Precursor lesions and
mycosis fungoides” September 2006
74. Guest speaker Think Tank on Response Criteria and Endpoints in Cutaneous Lymphoma focusing on Mycosis
fungoides (MF) and Sézary Syndrome (SS) November 16-17, 2006 Washington DC
75. Grand Rounds Speaker Loyola University, April 2007
76. Chair, lymphoma abstract session. World congress Buenos Aires October 2007
77. Speaker “life threatening dermatosis” symposium. World congress Buenos Aires October 2007
78. Speaker, “cutaneous lymphomas therapies” symposium World congress Buenos Aires October 2007
79. Speaker & Consultations in dermatopathology Am Society of Dermatopathology Annual meeting in Baltimore,
Oct 2007
80. Speaker Las Vegas Medical Dermatology Seminar SDEF “Update on the therapy of cutaneous lymphomas”
Nov 2007
81. Guest Speaker: International Symposium on Cutaneous Lymphomas. “Allogeneic hematopoietic stem cell
transplantation for the treatment of advanced cutaneous T cell lymphoma” Berlin, Germany. January 2008
82. Speaker: “Advanced Dermatopathology Symposium” American Academy of Dermatology San Antonio, Texas,
March 2008
83. Speaker: “Cutaneous lymphoma symposium: Ancillary tests in the diagnosis of cutaneous lymphomas”
American Academy of Dermatology San Antonio, Texas, March 2008
84. Speaker: “Advanced Medical Dermatology Symposium: Cutaneous lymphoid dyscrasias” American Academy
of Dermatology San Antonio, Texas, March 2008

Guitart, 15
85. Speaker: International Society of Cutaneous Lymphomas: “Allogeneic stem cell transplantation in CTCL” San
Antonio, Texas, March 2008
86. Speaker: International Society of Dermatopathology San Antonio, Texas, March 2008
87. Speaker: Hawaii Dermatological symposium SDEF: “ Update on CTCL”
88. Key note speaker Sociedad Dermatologica de Mexico: “Biologicals in CTCL” Guadalajara August 2008
89. Grand Rounds Speaker at Henry Ford Hospital Detroit, MI “Diagnostic and therapy of mycosis fungoides” Sep
2008
90. Grand Rounds Speaker at Wayne State University Detroit, MI “Diagnostic and therapy of mycosis fungoides”
Sep 2008
91. Speaker at CILAD (Iberoamerican Society of Dermatology) “Cytotoxic Cutaneous Lymphomas” Quito,
Ecuador October 2008
92. Guest Speaker: Miami Dermatological Society “CTCL: what’s new” September 2008
93. Speaker: “Cutaneous Lymphoid Dyscrasias” Department of Pathology Stanford University, Dec 2008
Research Grants
Co-PI “Cutaneous B-cell lymphomas” NMF 1997-98
Co-PI ” Early genetic events in PUVA-induced carcinogenesis” NMF 1997-99
C0-PI “ Cutaneous immunologic effects of topical Tacrolimus in atopic dermatitis” Fujisawa Pharmaceuticals
1997-98
Co-Investigator “Phase II trial of subcutaneous injections of interleukin-2 for the treatment of mycosis fungoides
and Sezary syndrome.1998-99
Co-Investigator “Phase II trial of Camphar-1 H in advanced cutaneous T-cell lymphoma, 1999-00
Co-investigator “Phase II trial of Temozolomide for the treatment of mycosis fungoides and the Sézary syndrome”
(1998-2000)
PI “ Multicenter randomized controlled study on Targretin combined with PUVA for the treatment of cutaneous T
cell lymphoma” Ligand Pharmaceuticals (2001-3)
PI “Epidemiology and molecular evaluation of cutaneous CD30+ T cell lymphomas” Chicago Dermatological
Society (2003-04)
PI “Use of Nitrogen Mustard for the treatment of mycosis fungoides stage I/IIa” Yaupon 2007-9
PI “ Interferon gamma secreting adenovirus vector for the treatment of cutaneous B cell lymphoma” Transgene
2006-8